Novo Nordisk stock climbs 1.52% as obesity drug Liraglutide shows promise in young kids
Novo Nordisk A/S shares climbed by 1.52% today to 888.60 DKK, following the release of promising new data on its obesity drug Liraglutide, which has ... Read More
Bayer and Sun Pharma join forces for new brand of Finerenone in India
In a significant development for the Indian healthcare sector, Sun Pharmaceutical Industries Limited and Bayer have announced a collaborative agreement to market and distribute a ... Read More
Lupin obtains tentative FDA approval for generic Canagliflozin Tablets
Global pharmaceutical leader, Lupin Limited, announced its significant achievement of receiving tentative approval from the United States Food and Drug Administration (U.S. FDA) for its ... Read More
FDA approves Zydus Lifesciences’ ZITUVIO tablets for Type 2 diabetes
Zydus Lifesciences Limited announced today that the U.S. Food and Drug Administration (FDA) has granted approval for its New Drug Application (NDA) for ZITUVIO (Sitagliptin) ... Read More
Biocon and Juno Pharmaceuticals ink game-changing diabetes drug deal
Biocon Limited, the innovation-driven global biopharmaceutical frontrunner, has made headlines by sealing a significant partnership agreement with Juno Pharmaceuticals, Canada's esteemed specialty pharmaceutical giant. This ... Read More
Abbott secures Bigfoot Biomedical to boost diabetes care tech
Abbott has wrapped up the previously announced acquisition of Bigfoot Biomedical. The latter which is a Silicon Valley-based front-runner is celebrated for its revolutionary smart ... Read More
Novo Nordisk acquires Embark Biotech and enters R&D collaboration to advance obesity treatments
Novo Nordisk, a global leader in healthcare, has acquired Embark Biotech, including its lead metabolic program, in a deal that further strengthens its portfolio in ... Read More
Sugar Watchers raises Rs 3.6cr led by ah! Ventures, targets diabetic market
Sugar Watchers, a burgeoning health brand specializing in Low Glycemic Index (Low GI) staples, has successfully raised INR 3.6 crores in a recent funding round ... Read More
Lupin acquires diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim
In a strategic move to fortify its position in the pharmaceutical domain, global major Lupin Limited proclaimed its acquisition of coveted diabetes brands ONDERO and ... Read More
Lilly expands portfolio with $1.9bn acquisition of Versanis Bio
In a move marking a significant expansion in the biopharmaceutical sector, Eli Lilly and Company (Lilly) has successfully completed the acquisition of Versanis Bio, a ... Read More